Elizabeth Hayes, Portland Business Journal
Molecular MD, a 10-year-old Portland diagnostics company, has raised $500,000 out of a $2 million offering, according to a filing with the U.S. Securities and Exchange Commission.
The company has contracts with all the major global pharmaceutical companies and helps bring new drugs through clinical trials and to market. The company works with academic research centers, including Oregon Health & Science University, to license new oncology biomarkers.
MolecularMD does clinical testing on blood and tissue samples sent to it from research centers from all over the world, as well as manufacturing test kits to sell to other sites.
This is far from the first fundraise for MolecularMD. It completed a $3 million Series A investment in 2008 and a $10 million Series B in 2012.